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Key Summary 
Established knowledge on this subject  
• Bacterial gastroenteritis quadruples the risk of developing IBS but the proportion 
of all IBS that is postinfectious is unclear 
• Risk factors include severity of initial illness, female gender and adverse 
psychological factors 
• What determines prognosis is uncertain 
What are the significant and/or new findings of this study? 
 • 13% of 7,811 IBS patients met criteria for postinfectious IBS 
• PI-IBS was associated with childhood hygiene, somatisation and living in Northern 
Europe / America  
• Prognosis in PI-IBS was not different from non-PI-IBS 
• High somatisation, female gender and living in North America and Northern 
Europe  were associated with lower recovery rates  
Abstract: 
Background: Gastrointestinal infection is an important risk factor for developing IBS.  
Our aim was to characterise postinfectious IBS (PI-IBS) compared to other IBS patients.  
Methods: An internet survey of  IBS patients using Rome III diagnostic questionnaire, 
Hospital Anxiety & Depression Scale (HADS) and Patient Health Questionnaire-12 
somatic symptom score (PHQ12-SS) documenting the mode of onset.  
Results: 7811 participants, 63.2% female of whom 1004 (13.3%) met criteria for PI-IBS. 
70% of PI-IBS described sudden onset, 35% onset while travelling, 49.6% vomiting, 
49.9 fever and 20.3% bloody diarrhoea. Compared to other IBS, PI-IBS was significantly 
associated with living in Northern Europe and North America, having a hysterectomy, not 
having an appendectomy, higher PHQ12-SS score and having more than one toilet in the 
family home. PI-IBS patients had more frequent stools. At 1 year recovery rate in PI-IBS 
and non-PI-IBS group was 19.7% and 22.2%, p=0.15. Recovery rates were lower for 
females (20.7%) versus males (38.8%),  those with somatisation ( 23.0%) versus those 
without (33.2%) and living in North America or Northern Europe (21.1%) versus living 
elsewhere (33.9%) p=<0.001. 
Conclusion: PI-IBS accounts for around 13% of all IBS in this internet sample, with some 
distinctive features but a similar prognosis to the remainder. 
  
Introduction 
IBS developing de novo after an acute infection in an individual with normal bowel 
function with gives an ideal opportunity to study the underlying mechanisms causing 
IBS. Earlier studies suggested that patients with postinfectious IBS (PI-IBS) would have 
a better prognosis and a lower frequency of psychological disorders compared to other 
IBS patients 1. However prospective studies found neuroticism, hypochondriasis2 
,depression 3 and somatisation4 all increase the risk. Recent meta-analysis has 
summarised the extensive literature finding that  the incidence of new IBS 12 months 
after infection was 10.1 (95% CI 7.2-14.1)% . The incidence appears higher after 
parasitic or protozoan infections at 49% compared to 13.8% after  bacterial 
gastroenteritis. Most studies agree that females and those with anxiety, depression or 
somatisation are at increased risk 5. Underlying possible mechanisms include ongoing 
increased permeability 6, abnormal serotonin metabolism3, ongoing chronic immune 
activation together with  altered microbiota 7   
We hypothesised based on previous studies (for review see 8) that PI-IBS would be most 
likely in those with severe gut inflammation. Many infections such as Campylobacter are 
less severe in childhood and lead to adaptive immunity9;10. We hypothesised that a rural 
upbringing and reduced hygiene in the family home during childhood would reduce the 
risk of PI-IBS. We also wanted to test the previous findings that psychological 
vulnerability was associated with PI- IBS and how this might impact on recovery rates. 
 
  
Methods 
This was an internet survey which allowed recruitment throughout the world and was 
funded by the United European Gastroentrology Federation, Gastro2009.  We created 
two identical web sites (http://www.pi-ibs.eu; http://www.postinfectious-ibs.eu) which 
provided bowel symptom questionnaires in 8 languages, namely English, Dutch, German, 
Belgian, Spanish (two versions: for Spain, for Mexico), Italian, Polish and Romanian.  
Ethics approval was sought for and received from the University of Nottingham Medical 
School Ethics Committee, Division of Therapeutics and Molecular Medicine, Nottingham, 
UK) (P/9/2008, as of Sept 26, 2008) conforming to the ethical guidelines of the 1975 
Declaration of Helsinki. Where legally required, national ethics board permissions were 
requested and received. Recruitment took place from December  5th 2008 with the main 
recruitment taking place within the first 3 years though more continued to accrue until 
the website was closed in January 2015.  
 
Inclusions and exclusions:  
Consecutive patients attending clinic were all invited to complete the survey online. 
Access to one of the web sites (www.pi-ibs.eu) was using a unique password for each 
patient provided by the investigators who all were specialists in functional GI disease; 
individuals without a password who found the website themselves without being directed 
there, entered the web at (www.postinfectious-ibs.eu). This allowed us to differentiate 
between patients with an investigator confirmed diagnosis of IBS using Rome III criteria 
and the rest  who responded yes to the question “Have you been  diagnosed with  IBS 
by a doctor?” The introductory information asked those with a history of major GI 
surgery, inflammatory bowel disease, colon cancer and taking drugs known to alter 
bowel function especially opiates and anticholinergics not to take part. Completing the 
questionnaire was accepted as giving informed consent. 
Questionnaire details: 
Participants were asked to answer questions of demographics including age, gender, 
country (of birth and also of current residence), schooling, current occupation, previous 
surgery and psychiatric treatment. We enquired about childhood living conditions 
including whether they shared a bed with their siblings or whether they had more than 1 
toilet or running hot water in the home. GI symptoms at the present time were 
documented with the Rome III IBS modular questionnaire 
(http://www.romecriteria.org/pdfs/AdultFunctGIQ.pdf), together with bowel frequency, 
days per week of urgency, bloating and their commonest stool form using the Bristol 
Stool Form Scale 11  
Details of diagnosis of postinfectious IBS: 
Participants were asked to describe whether their IBS symptoms began gradually or 
suddenly and if suddenly whether this was an infectious illness. Evidence to support a 
diagnosis of postinfective IBS included sudden onset of IBS after an infective episode 
diagnosed either by a positive stool culture showing a named organism or acute onset of 
new bowel symptoms associated with 2 or more of the following; fever, vomiting, 
diarrhoea, rectal bleeding or onset during foreign travel. Subjects were then asked to 
record their bowel habit before the acute episode using the Rome IBS module to 
determine whether they had IBS before the presumed infectious illness.  
Psychological assessments: 
Participants completed the Hospital Anxiety and Depression Scale (HADS)12 and the 
Patient Health Questionnaire-12 Somatic Symptom Scale (PHQ12-SSS) 13. Values of HAD 
anxiety or depression >7 and PHQ12-SS > 6 were considered abnormal. They were 
asked to provide a contact email address to which a second questionnaire would be sent 
out 1 year later. Provision of the email was taken as permission to do so. Data is 
reported showing the total population and then those with postinfectious IBS (PI-IBS) 
compared with those with non-postinfectious IBS (Non-PI-IBS).  
Analysis 
Duplicate entries were removed and country of origin recoded as either Northern Europe 
(defined as North of Alps or Pyrenees) and North America OR the rest of the world. 
We present summary statistics as proportions for categorical variables which we have 
compared using chi squared tests, and as means and standard deviations or medians 
and interquartile ranges for normally and non-normally distributed continuous variables 
which were tested using t-tests or Wilcoxon’s rank sum respectively. We went on to 
carry out multivariable analyses using logistic regression to examine potential 
confounding of the relationships between PI-IBS and prognosis. 
 
Results 
There were a total of 7836 lines of data in the dataset, and after exclusion of 75 
duplicate email addresses and 209 lines with duplicate IP address, age and gender this 
provided a total of 7,552 subjects. The majority of cases came from the investigators 
countries with the largest numbers from Italy(46%) , Netherlands (14%), Germany 
(8%) and Spain (6%) but there was at least one return from 107 countries. 63% met 
strict Rome III criteria but 37% did not despite having had a diagnosis of IBS by their 
doctor.  
 
Similarity of subjects with and without a password 
 
The 2622 (34.72%) of subjects who had a password to access the questionnaire did not 
differ from those without a password in the proportion meeting Rome III criteria which 
was 1648 of 2622 (62.9%) and 3097 of 4930 (62.8%) respectively. There were minor 
differences between these two groups, those without a password were more likely to be 
female (66.6% versus 56.1%, p<0.001) and were slightly older (mean 40.8 years 
versus 39.9 years p=0.0058). They were also less likely to score abnormally high on the 
HADS anxiety scale (84.7% versus 87.6%, p=0.003) though more likely to score 
abnormally high on the PHQ12-SS scale (61.4% versus 57.1%, p=0.002).  
 
Diagnosis of PI-IBS 
A total of 1,080 subjects met our definition of PI-IBS and after excluding 76 with prior 
IBS the proportion of IBS that was PI-IBS was 1,004/7,552 (13.3%).Those with PI-IBS 
were slightly more likely to meet the Rome III criteria than those without (68.5% vs 
62.0% respectively P<0.001), they had however a similar gender distribution (63% 
female for both PI-IBS and non-PI-IBS) and age (median age 38 IQR 29-49 for PI-IBS 
and median 38 IQR 30-49 for non-PI-IBS). Table 1 shows the frequency of features used 
to diagnose PI-IBS.  The commonest feature was sudden onset which was seen in 72% 
followed by fever, vomiting and onset during travel. Only 24% had a positive stool 
culture. Most of those meeting our criteria, met 2 (62%), with 27% meeting 3 criteria 
and 11% 4 or more.  When asked "Do you remember how your doctor treated your 
infection?” only 713 recorded a response. 293 replied that they received no specific 
treatment, 275 received antibiotics , 35 probiotics and 45 Loperamide with 65 reporting 
other drugs. Those taking antibiotics were slightly more anxious than those taking no 
treatment with HADS scores of 10.9±2.7 and 10.6±2.7 respectively, p=0.036. Antibiotic 
usage was significantly increased in of those with bloody diarrhoea 12.2% of whom took 
antibiotics while just 3.2% with  no blood in their stools took antibiotics, Fisher’s exact 
test, p < 0.001.  
Differences between PI-IBS and non-PI-IBS 
 
Current GI symptoms 
 
PI-IBS patients tended to have more stools per day,  median (IQR) being 2(1-3) 
compared to 1.5(1-3) (p=0.0002, Mann Whitney U test). Comparing both the hardest 
and softest forms recorded as typical between the groups, distributions were similar for 
PI-IBS and non-PI-IBS (both p>0.05). Subjects reported the frequency of loose and hard 
stools on a 5-point scale ranging from never or rarely to always. PI-IBS reported 
significantly more frequent the passage of loose stools (Figure 1, p=0.03) but not hard 
ones (p=0.716).  
Psychometrics 
The total HADS scores and anxiety or depression sub scores were similar between 
patients with and without PI-IBS (See Table 2). A high proportion of patients were being 
treated for anxiety both  PI-IBS (77.4%) and   non-PI-IBS (74.5%), (difference not 
significant p=0.051). Treatment for depression was also common but in this case those 
with PI-IBS were slightly less likely to be treated 79.3% versus 82.0% (p=0.04). 
Respecting somatisation, a significantly greater proportion of PI-IBS scored above the 
upper limit of normal for the PHQ12-SS scale (6), 64.3% versus 59.0% (p=0.002).  
Childhood environment, surgical history and PI-IBS 
Childhood living conditions as assessed by having running hot water in the home, having 
to share a bed as a child or having contact with animals were not associated significantly 
with PI-IBS (Table 2), and having more than one toilet was commoner in PI-IBS being 
reported in 50.1% versus 45.9% in non-PI-IBS (p=0.004). PI-IBS patients were more 
often from an urban childhood environment (67.1% vs 63%, p=0.011). As can be seen 
in Table 2 59% of PI-IBS came from Northern Europe or North America, significantly 
more than the 37% of non-PI-IBS. PI-IBS was also significantly associated with  a 
history of hysterectomy among women and was negatively associated with a history of 
appendicectomy. 
 
Follow up data 
Of the initial 7552 subjects 3,256 provided an email address indicating they were 
prepared to do a repeat symptom survey at 1 year. We obtained follow up data after 1 
year on 1,056 (32.43%) of these of whom 200 (18.9%) met our definition of PI-IBS. Of 
the 846 who met Rome III criteria initially 618 still met the criteria at one year so that 
the rate of spontaneous remission was 27% in the year. The proportion who improved 
(as judged by ceasing to meet these criteria) varied across the age groups from 23% in 
those aged 21-30 to 37.5% in those aged over 70, these differences were however not 
significant (p=0.18). Significant effects on recovery rates were seen for gender, 
somatisation and country of origin (Figure 2). Significantly more males (38.8%) ceased 
to meet Rome III than females (20.7%) (p<0.001). Those with somatisation, indicated 
by  an abnormally high PHQ12-SS score, were significantly less likely to recover than 
those without somatisation, remission rates being 23.0% versus 33.2 % respectively, 
p<0.001  The remission rate in PI-IBS at 22.8%, was not significantly different from that 
in the non-PI-IBS group at 27.9% (p=0.19).  
Remission of symptoms was significantly less in those from North America / Europe 
21.1% compared to those from elsewhere 33.9% ( Table 3). A multivariable logistic 
regression adjusting the effect of PI-IBS upon improvement for the effects of the other 
variables showed only slight confounding by them: Odds ratio for still being Rome III for 
PI-IBS versus non-PI-IBS was 1.31 (0.87-1.95) in univariate analysis, and 1.14 (0.75-
1.75) in multivariate regression. If we altered the definition of improvement to be a 
reduction in abdominal pain over the previous 3 months, or reductions in the number of 
hard or of loose stools, we similarly found that some individuals improved while others 
got worse but there was no significant association with PI-IBS according to our 
definition. Finally, we repeated analyses defining PI-IBS either as only those with a 
positive stool culture at onset, or as patients who self identified as PI-IBS. Again, no 
significant difference in prognosis was noted (data not shown). 
Longer duration of IBS symptoms reduced recovery rates. 272 had IBS onset 0-3 years 
before the survey of whom 38% recovered at the 1 year follow up while 819 had onset 
>3 years before and of these just 25% recovered, Chi2=3.3, p=0.07. 
In view of the response rate of only 32.43% at follow up we compared baseline data for 
those with and without follow up. Amongst those providing email addresses, those 
providing follow up were slightly older (mean age 43.2 vs 39.9, p<0.001), more likely to 
satisfy Rome3 criteria (80.1% vs 72.6%, p<0.001), more likely to be from northern 
Europe or the USA (52.1% vs 31.7%, p<0.001) but less likely to have an abnormal 
PHQ12-SS score (59.7% vs 64.6%, p=0.007, gender and HAD sub scores (or overall) 
were not significantly different. 
 
Discussion 
This large pragmatic study of IBS, PI-IBS and its prognosis found that about 13% of 
included cases satisfied criteria suggestive of PI-IBS. The commonest diagnostic feature 
was sudden onset followed by vomiting and fever but only 24% reported having a 
positive stool culture. Compared to non-PI-IBS cases, PI-IBS had greater stool frequency 
and looser stools which is in keeping with earlier reports that the commonest IBS 
subtype in  PI-IBS was IBS-D 3 14.  Whether this is related to the common axis of 
dysbiosis in which PI-IBS and IBS-D overlap remains to be determined 7. Those with PI-
IBS had a slightly greater tendency to somatise, a lower rate of previous 
appendicectomy and a higher rate of hysterectomy. They were also more likely to have 
lived in an urban environment and in a house with multiple toilets during childhood, and 
more likely to be from Northern Europe or North America. Contrary to our hypothesis PI-
IBS was not associated with a significantly improved prognosis.  We were however able 
to show that prognosis is better in those without somatisation, in males, and in those not 
from Northern Europe and North America.  
Subjects who used a password to access the questionnaire were known to be from 
participating clinics diagnosed by the authors and their colleagues, (all experts in 
functional gastrointestinal diseases) and their diagnoses were therefore of known 
validity. We found no difference between those with and without password as regards to 
meeting our gold standard for IBS diagnosis (namely the Rome III criteria). This 
encourages us to believe that those who took part without a password were also likely 
truly to suffer from IBS, i.e. to believe that they were valid cases to study.  This lack of 
difference also reassured us that subjects from investigators clinics were not grossly 
atypical (a risk when examining the practice of those with a special interest in the area). 
Where we have limited analysis to those using passwords, the results should be 
generalisable to patients with IBS seen in the secondary care. An inevitable limitation to 
our study is that we have recruited exclusively patients prepared to complete a quite 
lengthy survey, who may not be typical of all patients.  
There was a risk that our survey would selectively recruit those with a postinfectious 
origin however we do not believe this is the case for a number of reasons. Firstly the  
proportion that were PI-IBS 14% is within the range of 6-17% reported by others using 
a number of different recruitment techniques 15. Secondly others have modelled the 
proportion of IBS that is PI-IBS and using the most conservative model concluded that 
9% of IBS was postinfectious16.  Finally although the website was labelled “piibs” we 
don’t think the general public would necessarily recognise  these initials and questions 
about infection only appear in the middle of quite extensive set of questions about other 
factors.  
Though only 28% of our PI-IBS cases reported a positive stool culture, the absence of 
this does not excludes the diagnosis of PI-IBS since it is common practice only to 
request stool culture in cases of acute gastroenteritis which are not settling. One 
prospectively survey in the UK  found that stool samples were only requested in 27% of 
gastroenteritis cases presenting to primary care17 so the rate of culturing for all cases 
must be much lower given that many do not seek health care. To examine the possibility 
of bias we varied our definition of PI-IBS to include only those with positive stool 
cultures but this did not appreciably alter our results. We therefore think it unlikely that 
our definition of PI-IBS has greatly biased the results, and in addition as the criteria we 
used mirror those we would commonly use in clinical practice, we feel our results are 
likely both to be valid and to be informative to clinicians.  
We found PI-IBS cases to have more frequent bowel movements but to be remarkably 
similar to non-PI-IBS with respect to age, gender and anxiety though they were less 
likely to have been treated for depression. Contrary to our original hypothesis we found 
no evidence that remission at 1 year differed from non-PI-IBS being 22.8% and 27.9% 
respectively.  
Childhood living conditions were generally good with for example 86% having hot 
running water in their homes but we did find that having more than one toilet in the 
home was slightly commoner in PI-IBS than non-PI-IBS partially supporting the idea that 
childhood affluence might increase ones risk of developing PI-IBS.  
This might explain why the proportion of PI-IBS that was from  Northern Europe / North 
America (59%) was  significantly higher than the 37.4% of non-PI-IBS (p<0.001). An 
alternative explanation is that one third of PI-IBS develops during foreign travel which 
might occur for frequently in those from the more affluent  Northern Europe/ North 
America. Campylobacter is the commonest cause of PI-IBS in adults in the UK at least 18.  
However the majority of Campylobacter infections in tropical countries occur in 
childhood19 when they are often mild with a few days of watery diarrhoea.  A similar mild 
character was reported in adult patients infected with Campylobacter jejuni from 
southern Spain with 96% having only watery diarrhoea20. By contrast adults with 
Camplyobacter jejuni infection in the US experience a severe illness with mucosal 
ulceration21  and one third of adult cases in the UK have bloody diarrhoea and weight 
loss18 indicating severe mucosal inflammation which might be more likely to result in 
prolonged bowel dysfunction.   Whether these differences represent  differences in 
bacterial or host characteristics remains to be determined. 
The prognosis in PI-IBS did not differ from non PI-IBS with recovery in approximately 1 
in 4 in the first year. However males were almost twice as likely as females to recover in 
the first year, a striking as yet unexplained difference which should be further explored. 
However the response rate for the follow up study was low at 14% (32% of those 
originally indicating a willingness to consider further contact) which does introduce a risk 
of bias. Our analysis of the difference between responders and non-responders shows 
that of the factors we have found to be associated with prognosis, gender is not 
associated with response, and the excess of Europeans and North Americans might bias 
towards a worse prognosis whereas the deficit of somatisers would bias in the other 
direction. Few other surveys have attempted such follow up so there is limited data with 
which to compare our recovery rate but 27% at 1 year is within the range reported in 
meta-analyses of postinfectious IBS22. 
Although we found few major differences in clinical features between PI-IBS and non-PI-
IBS it is still important to recognise the condition both to reassure the patient that this is 
not unusual and also because there is a hint that response to treatment might be 
different. A recent trial of an anti-inflammatory agent mesalazine showed overall no 
benefit in IBS with diarrhoea but a post hoc subgroup analysis did suggest that PI-IBS 
did respond 23. This needs repeating but makes sense if the underlying pathophysiology 
of PI-IBS includes ongoing low grade inflammation.  
 
 
 
 
 
 Legend for Figures 
Figure 1 
Frequency of loose stools  as rated by subjects on a 5 point scale was increased in PI-IBS, Chi squared test,  p=0.03 
Figure 2 
Remission rates of IBS symptoms were worse for females, those with abnormal PHQ12-SS and those residing in North America and 
Northern Europe (NA/N Europe). *** p=0.001   
  
 
  
 
  
Table 1 Frequency of  PI-IBS criteria % 
 PI-IBS Non-PI_IBS 
Sudden onset 72.4 16.8 
Onset during travel 34.5 2.8 
Vomiting 50.1 4.4 
Fever 50.6 2.4 
Bloody diarrhoea 19.4 2.4 
Stool culture positive 24.0 1.8 
   
Table 2 Univariate associations of PIIBS at baseline questionnaire 
 PI-IBS Non-PI-IBS P 
Number 1004 6548  
Age (Median(IQR)) 38 (29-49) 38 (30-49) 0.33 
    
HADS Anxiety score (Median(IQR)) 11 (9-13) 11 (9-13) 0.40 
HADS Depression score (Median(IQR)) 10 (8-11) 10 (8-11) 0.06 
PHQ12-SS (Median(IQR)) 8 (5-11) 7 (5-11) 0.003 
    
    
History of cholecystectomy 6.0% 4.7% 0.075 
History of Appendicectomy 14.1% 17.2% 0.016 
History of Hysterectomy (in women) 8.2% 5.2% 0.002 
    
Characteristics of childhood home    
Contact with animals 8.37% 8.15% 0.813 
More than one toilet 50.8% 45.9% 0.004 
Running hot water 89.5% 90.6% 0.292 
Shared a bed 13.7% 12.3% 0.225 
Urban 67.1% 63.0% 0.011 
    
Geographic origin    
N Europe and USA 59.1% 37.3% <0.001 
  
Table 3 Univariate associations of recovery of IBS as measured by ceasing to be 
ROME3 positive among those with follow up data who were Rome 3 +ve at outset 
 Rome 3 -ve at FU % p 
Total  228 27  
    
Male 113 38.8 <0.001 
Female 115 20.7  
Age bands    
0-20 1 33.3 0.29 
21-30 39 23.4  
31-40 62 26.2  
41-50 51 23.6  
51-60 45 32.4  
61-70 20 33.9  
>70 9 37.5  
Country of residence    
N Europe/America 96 21.1 <0.001 
Rest of the world 132 33.9  
    
HADS anxiety    
Normal 27 24.55 0.54 
Abnormal 201 27.31  
HADS depression    
Normal 33 33.67 0.11 
Abnormal 195 26.07  
PHQ12-SS    
Normal 108 33.2 0.001 
Abnormal 120 23.0  
Subtype of IBS    
PI-IBS 37 22.8 0.19 
Non PI-IBS 191 27.9  
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